| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Entasis Therapeutics Holdings Inc. | Chief Commercial Officer | Common Stock | 0 | $2.20 | 11 Jul 2022 | Direct | |
| Entasis Therapeutics Holdings Inc. | Chief Commercial Officer | Stock Option (right to buy) | 0 | 11 Jul 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000110465922078803-triola-anna-diaz-2022-07-11 | Entasis Therapeutics Holdings Inc. | 11 Jul 2022 | 2 | $0 | 4 | Chief Commercial Officer | 11 Jul 2022, 16:10 |
| /report/000110465922005407-triola-anna-diaz-2022-01-18 | Entasis Therapeutics Holdings Inc. | 18 Jan 2022 | 1 | $0 | 4 | Chief Commercial Officer | 19 Jan 2022, 15:00 |
| /report/000110465921093949-triola-anna-diaz-2021-07-19 | Entasis Therapeutics Holdings Inc. | 19 Jul 2021 | 1 | $0 | 4 | Chief Commercial Officer | 20 Jul 2021, 16:06 |
| /report/000110465921093948-triola-anna-diaz-2021-07-19 | Entasis Therapeutics Holdings Inc. | 19 Jul 2021 | 0 | $0 | 3 | Chief Commercial Officer | 20 Jul 2021, 16:05 |